Sanofi Call for telent and Seminar: "Sanofi Translational Science Hub: Transforming mRNA vaccine development"
Come and meet the Sanofi team on Monday 13 February and learn about job opportunities at the Translational Science Hub.
You will have the chance to hear from Dr Saranya Sridhar, Sanofi’s Head of Translational Medicine, who will provide an overview of the TSH and Sanofi’s plans to transform mRNA vaccine development.
The Translational Science Hub is being established under an agreement between Sanofi, the University of Queensland, Griffith University and the Queensland Government. The hub will be located at various sites, including at TRI, The University of Queensland and Griffith University.
This seminar will include a Q&A session, and will be followed by networking drinks in the TRI Atrium.
When: 4:30pm – 6:30pm Monday 13 February 2023
Where: TRI Auditorium & Atrium
Who: Everyone in the TRI Community is welcome. Registrations are essential for catering purposes
Register: Via Eventbrite
Saranya Sridhar, MBBS, MS, D.Phil, DFPH
Head of Translational Medicine at Sanofi Vaccines and Global Head for COVID-19 and mRNA Vaccines Clinical Franchise
Saranya Sridhar is the Head of Translational Medicine at Sanofi Vaccines and Global Head for COVID-19 and mRNA Vaccines Clinical Franchise. In this role, he has led the clinical development program to license Sanofi’s COVID-19 vaccine. As Head of Translational Medicine, his team’s focus is on translational clinical research and early development on optimising the mRNA vaccine technology and understanding the mechanism of action of mRNA vaccines. He has worked on late-stage development and approval of the dengue vaccine and using machine-learning to develop next-generation influenza vaccines. His expertise is in early and late clinical development, with particular interest in respiratory pathogens.
Dr Sridhar earned his medical degree in India and was then awarded a Rhodes Scholarship to pursue a PhD at Oxford University, where he worked on developing adenoviral vectored vaccines for malaria and tuberculosis. He completed a Masters in Epidemiology as part of a Fogarty International HIV Training Fellowship from the University of California at Berkeley. Dr Sridhar joined Sanofi after completing Fellowships at Imperial College London and the Jenner Institute, Oxford, where he worked on T cell correlates of protection and T-cell-focused vaccines against influenza and tuberculosis.
He is a GMC registered physician in the UK and a Member of the UK Faculty of Public Health.
